-
公开(公告)号：US20250057920A1
公开(公告)日：2025-02-20
申请号：US18249932
申请日：2022-03-22
Applicant: CHIANG MAI UNIVERSITY , SURANAREE UNIVERSITY OF TECHNOLOGY
Inventor： Chatchai TAYAPIWATANA , Umpa YASAMUT , Montarop YAMABHAI , Vannajan Sanghiran LEE
Abstract: A modified or bioengineered protein of a modified interferon gamma (IFN-γ) related to at least one modification. Preferably, the modified IFN-γ comprises at least one modification of an amino acid located at a position of 27 to 40 of a sequence as setting forth in SEQ ID NO. 1. The modified IFN-γ is capable of initiating cellular signaling towards an immune response upon being administered to a subject.
-
公开(公告)号：US20250057760A1
公开(公告)日：2025-02-20
申请号：US18934892
申请日：2024-11-01
Applicant: Neurotech USA, Inc.
Inventor： Jeffrey Louis GOLDBERG , Cahil Mcgovern , Weng Tao , Konrad A. Kauper
Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
-
公开(公告)号：US20250027107A1
公开(公告)日：2025-01-23
申请号：US18702197
申请日：2022-10-18
Applicant: FLAGSHIP PIONEERING INNOVATIONS VII, LLC
Inventor： Alexandra Rachael Sneider , Jacob Rosenblum Rubens , Narahari Subbanna Pujar , Molly Krisann Gibson , Benjamin Andrew Portney , Geoffrey A. von Maltzahn , Camilo Ayala Breton
Abstract: The disclosure provides, for example, single stranded, covalently closed DNA that does not form a double stranded structure longer than 100 base pairs. The ssDNA may encode an effector sequence, for instance a therapeutic protein. The ssDNA may comprise a nuclear targeting sequence (NTS). In some embodiments, the ssDNA shows decreased activation of the innate immune system compared to an otherwise similar dsDNA.
-
4.发明申请公开(公告)号：US20250018062A1
公开(公告)日：2025-01-16
申请号：US18760652
申请日：2024-07-01
Applicant: Moderna TX, Inc.
Inventor： Antonin DE FOUGEROLLES , Justin GUILD
IPC: A61K48/00 , A61K9/127 , A61K9/14 , A61K9/51 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/21 , A61K38/45 , A61K38/48 , A61K47/54 , C07H21/02 , C07K14/005 , C07K14/435 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/705 , C07K14/745 , C07K16/00 , C07K16/28 , C07K16/40 , C12N9/00 , C12N9/02 , C12N9/10 , C12N9/12 , C12N9/16 , C12N9/24 , C12N9/42 , C12N9/64 , C12N9/68 , C12N9/88 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
-
公开(公告)号：US20250009779A1
公开(公告)日：2025-01-09
申请号：US18699060
申请日：2022-10-12
Applicant: NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL S
Inventor： Franck Barrat , Lionel Ivashkiv
IPC: A61K31/7072 , A61K31/20 , A61K31/343 , A61K31/365 , A61K31/403 , A61K31/405 , A61K31/4706 , A61K31/501 , A61K31/52 , A61K31/573 , A61K31/675 , A61K31/7068 , A61K38/13 , A61K38/21 , A61K39/42 , A61P31/14 , A61P37/02
Abstract: This disclosure features methods to treat viral diseases and/or hypercytokinemia using compounds that disrupt the tricarboxylic acid (TCA) cycle and/or compounds that activate the unfolded protein response (UPR) in immune cells such as plasmacytoid dendritic cells. In some embodiments, the immune cells are dendritic cells, macrophages, T cells, B cells, natural killer cells, and/or neutrophils.
-
Patent Agency Ranking
公开(公告)号：US20240415880A1
公开(公告)日：2024-12-19
申请号：US18603593
申请日：2024-03-13
Applicant: Norman A. Brooks
Inventor： Norman A. Brooks
IPC: A61K33/30 , A61K31/138 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K33/243 , A61K36/66 , A61K38/14 , A61K38/21 , A61K47/38 , A61M25/00 , A61M25/10
Abstract: An improved method for treating breast cancer using zinc chloride as an alternative to radiation is provided. Zinc chloride is a deeply penetrating topical medicine that kills cancerous tissue equivalent to radiation. Radiation is time-consuming, costly, and can cause severe radiation-related adverse events, including secondary cancers, lung, and heart damage. An analysis of 20,000 women showed that radiation was able to reduce mortality by 13.2% from breast cancer, but this improvement was offset by radiation mortality from adverse events of 21.2% [Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials, Lancet 2,000:355: May 20, 2000]. This invention allows the surgeon to destroy residual malignant tissue that surrounds a breast cancer lumpectomy wound equivalent to radiotherapy without the mortality of radiation.
-
公开(公告)号：US20240408178A1
公开(公告)日：2024-12-12
申请号：US18731677
申请日：2024-06-03
Applicant: Ainos, Inc.
Inventor： Tsung-Fu YU , Chun-Hsien TSAI , Ting-Chuan LEE
Abstract: Provided is a low-dose interferon composition for treatment or prevention of conditions, diseases or disorders associated with inflammation in cat. The composition comprises a total concentration of human interferon-α2b in a range of 160 IU/ml to 100,000 IU/ml. The composition is orally administered buccally.
-
公开(公告)号：US20240398901A1
公开(公告)日：2024-12-05
申请号：US18733102
申请日：2024-06-04
Applicant: AINOS INC. TAIWAN BRANCH (USA)
Inventor： Tsung-Fu YU , Yi-Yu TIEN , Chun-Hsien TSAI , Ting-Chuan LEE , Chun-Jung TSAI
Abstract: The present application provides a process for manufacturing an orally disintegrating tablet (ODT) comprising a cytokine as an active pharmaceutical ingredient comprising: acidifying an excipient, conducting a first granulation step of the acidified excipient to obtain acidic powders, and conducting a second granulation step by mixing the acidic powders and the cytokine to obtain granules containing the cytokine. The present application also provides an ODT manufactured by the process.
-
公开(公告)号：US12156938B2
公开(公告)日：2024-12-03
申请号：US16982990
申请日：2019-03-20
Applicant: Universiteit Twente
Inventor： Jai Prakash , Peter Van Hoogevest , Gerrit Storm
Abstract: A composition comprising a liposome comprising a first phospholipid comprising a C14-C19:0 fatty acid and a C3-C15:0 fatty acid with a c-terminal carboxyl or a carboxaldehyde group; a second phospholipid comprising a C14-C19:0 fatty acid and a C14-C19:0 fatty acid and a sterol. The first phospholipid is preferably a phosphatidylcholine. The second phospholipid is preferably HSPC and the sterol is preferably cholesterol. In some embodiments, the molar ratio of the respective ingredients is 2-3:5-6:2-3; preferably 2:6:2; or 3:5:2, respectively. The invention also relates to the use of this composition in the targeting of M2 macrophages.
-
公开(公告)号：US20240358797A1
公开(公告)日：2024-10-31
申请号：US18656385
申请日：2024-05-06
Applicant: Kernal Biologics, Inc.
Inventor： Monia DRAGHI , Rudy CHRISTMAS , Cafer OZDEMIR , Burak YILMAZ , Yusuf ERKUL , Manfred KRAUS
CPC classification number: A61K38/212 , A61K9/5123 , A61K38/1709 , A61K38/2013 , A61K38/208 , A61K38/2086 , A61K48/005 , A61P35/00
Abstract: The present disclosure provides technologies for achieving treatment of cancer. The present disclosure provides methods and compositions for the treatment of cancer using oncoselective construct designs that can be used to encode payloads of high therapeutic interest. The present disclosure recognizes that treatment of individuals suffering from cancer with engineered nucleic acids of the disclosure in combination with immune checkpoint therapy provides unique advantages.
-
-
-
-
-
-
-
-
-
Search Results
5430
records
(took 0.071 seconds)
